AllDocs -> cancers

Preserving the Power of Antibiotics SM February 20, 2004 Dr. Stuart Levy's Comments on Article Suggesting Breast Cancer is Linked to Use of Antibiotics An article by Velicer and colleagues in the February 18 issue of the Journal of the American Medical Association reports a statistically significant increased risk of breast cancer among women who have taken antibiotics as compared to a control group that did not. The risk increased with the numbers of days the individuals used an antibiotic. The relationship held for all antibiotics monitored. The findings are intriguing. While not demonstrating a cause and effect relationship, the data do ask: what are the reasons for this association? Is there another unknown factor(s) which distinguishes some women taking antibiotics from those who do not? Could it be specific to women prone to breast cancer ? ...

HRT website v5 070803 EMBARGOED UNTIL 00:01 FRIDAY 080803 HORMONE REPLACEMENT THERAPY AND BREAST CANCER NEW ADVICE FROM THE COMMITTEE ON SAFETY OF MEDICINES A large research project, the “Million Women Study”, provides important new information on the risk of breast cancer in association with using hormone replacement therapy (HRT). The Committee on Safety of Medicines (CSM) and its expert working group on HRT has considered these new facts and is issuing advice to prescribers and women. This new information relates to the risks of breast cancer in users of HRT, including oestrogen only HRT, combined (oestrogen plus progestagen) HRT and tibolone (Livial® - a different type of HRT). In line with previous findings, the new study has confirmed that oestrogen-only products are associated with a small increase in the risk of breast cancer . For combined HRT, the increase in risk ...

R Gene Expression Profiles of Human Breast Cancer Progression Xiao-Jun Ma*, Ranelle Salunga*, J. Todd Tuggle*, Justin Gaudet†‡§, Edward Enright*, Philip McQuary*, Terry Payette*, Maria Pistone*, Kimberly Stecker*, Brian M. Zhang*, Yi-Xiong Zhou*, Heike Varnholt†, Barbara Smith‡, Michelle Gadd‡, Erica Chatfield†, Jessica Kessler†, Thomas M. Baer*, Mark G. Erlander*§ & Dennis C. Sgroi†§ *Arcturus, †Department of Pathology, Harvard Medical School, Molecular Pathology Research Unit, Massachusetts General Hospital, ‡Department of Surgery, Harvard Medical School, Massachusetts General Hospital Abstract Although distinct pathological stages of breast cancer have been described, the molecular differences among these stages are largely unknown. Here, through the combined use of laser capture microdissection (LCM) and DNA microarrays, we have generated in situ gene expression profiles of the pre-malignant, ...

Y-ME NATIONAL BREAST CANCER ORGANIZATION NORTHEASTERN OKLAHOMA AFFILIATE NEWS August 2003 Meet our New Development Coordinator Louan Torres comes to us with over 15 years of experience in the non-profit fundraising arena. As the Development Coordinator for Y-ME of Northeastern Oklahoma, Louan is leading the local fund raising efforts, implementing local marketing efforts, and maintaining community contacts. She is working to generate the funds to keep our affiliate’s quality programs strong. As the senior staff member in our office, she is working closely with our Administrative Assistant, Ann Rose, and the board of Directors. Reach Louan at the office (918-481-4838) or electronically at ltorres@y-me.org . She would love to hear from you as she works to help us build and maintain our affiliate presence to ensure through information, ...

The latest information on research, issues and concerns surrounding breast cancer . Give the Gift of Hope We hope that you will remember Y-ME National Breast Cancer Organization with your gifts this holiday season. You will enjoy knowing that your generosity makes a difference in the lives of those touched by breast cancer , including the more than 200,000 women who were diagnosed this year alone. Here's how you can give this holiday season: 1. Appreciated assets including stocks, bonds or shares of mutual funds make wonderful gifts. If you have owned shares for at least a year and a day, you can take a full fair market deduction for your charitable gift and pay no capital gains tax. 2. Make a donation online in honor or in memory of someone. Simply visit www.y-me.org and click on the “Ways to Give” icon. 3. Or simply send a ...

New and Emerging Technology Briefing Theratope for breast cancer July 2002 Horizon Scanning Review Early assessments of new or emerging technologies contain time-limited information and should be used with due caution. Not to be used for commercial purposes National Horizon Scanning Centre Page 2 National Horizon Scanning Centre THERATOPE July 2002 2 Theratope for Breast Cancer The technology Theratope (adenocarcinoma vaccine, STn-KLH) – Merck Pharmaceuticals/Biomira, is a therapeutic vaccine in phase III trials for the treatment of breast cancer . Theratope incorporates a synthetic mimic of sialyl Tn (STn), the antigen found on cancer cells associated with disease aggression. The synthetic antigen is combined with a carrier molecule, keyhole ...

CONTACT: Suzanne Barwick (850) 645-5789 BREAST CANCER SCREENING GETS BOOST WHEN POTENTIAL LOSS IS POINTED OUT TALLAHASSEE, Fla., -- Women who are told what they could lose by not being screened for breast cancer were almost seven times more likely to get a mammogram than those not exposed to such a message, according to College of Human Sciences researchers. Framing a message that promotes screening in terms of potential loss, or a “loss-frame” approach, was part of a behavioral research grant funded by the American Cancer Society. This is the opposite approach to that taken by most public health campaigns, which typically promote the benefits of proper health behaviors, said Doris Abood, NFES associate professor, and Ann Mullis, FCS associate professor. Failing to address the consequences of NOT engaging in certain health behaviors may create complacency in people ...

November/December 2002, Vol. 9, No. 6 480 Cancer Control The Use of Bisphosphonates in Patients With Breast Cancer Catherine H. Van Poznak, MD Background: Bone is the most common site of breast cancer metastases. Skeletal metastases may be associated with harmful and painful events such as fractures, spinal cord compression, and hypercalcemia. By inhibiting osteoclasts and bone resorption, bisphosphonates can interrupt the process of bone destruction and decrease the risk of skeletal complications. Methods: A review of the literature was undertaken regarding the use of bisphosphonates in breast cancer management, with particular attention to prospective, randomized clinical trials that have influenced the treatment of bone metastases. Results: Large prospective, randomized trials have demonstrated that bisphosphonates are effective in reducing ...

NSW Multicultural Health Communication Service website: http://mhcs.health.nsw.gov.au e-mail: mhcs@sesahs.nsw.gov.au phone: (02) 9382 8111 to consult a female breast surgeon, her GP may be able to refer her to one. Can men develop breast cancer ? Yes. Although less com- mon among men, more than 50 men develop the disease in Australia each year. Men who notice any changes such as a lump or thickening in the breast area should see their doctor. For more information, ring one of the following services. * The Multicultural Breast Cancer Information Service has bilingual workers available as follows: Arabic (Mondays, Tuesdays, Wednesdays, Thursdays) (02) 9334 1961 or 1300 301 625. Cantonese and Mandarin (Monday and Tuesday (02) 9334 1855 or 1300 300 935. Italian Thursday and Friday (02) 9334 1983 or 1300 301 431. Greek (Thursday and Friday (02) 9334 1863 or 1300 ...

Vol. II, No. 5 Feb. 1, 2001 continued on page 3 1 continued on page 3 continued on page 2 Women Who Hit the Road During Breast - Cancer Therapy Stay Fit OTTAWA—Exercise ad libitum during adjuvant therapy for early breast cancer seems to fight off fatigue and feelings of dependence. An oncology rehab group here found that women asked to exercise on their own during therapy got a jump start toward keeping themselves from sinking into a physical and emotional funk. The exercisers—many taking potentially cardiotoxic doxorubicin—did signifi- cantly better in cardiac and overall conditioning than those advised to rest to relieve the weight of the arduous therapy, Dr. Roanne Segal, medical director of the Ottawa Regional Cancer Center, and colleagues reported in the Feb. 1 Journal of Clinical Oncology. Among 123 women with Stage I or II breast cancer , ...

Eur J Gen Med 2004; 1(2): 11-14 ANTITHYROID ANTIBODY LEVELS IN PATIENTS WITH BREAST CANCER Haluk Dülger 1 , Süleyman Alici 2 , Ekrem Algün 3 , Ömer Etlik 4 , Mehmet Sayarlioglu 5 , Ekrem Dogan 5 , Hayriye Sayarlioglu 5 , M. Ramazan Sekeroglu 1 Yüzüncü Yil University, Faculty of Medicine, Departments of Biochemistry 1 , Medical Oncology 2 , Endocrinology 3 , Radiology 4 and Internal Medicine 5 ORIGINAL ARTICLE Breast cancer is a hormone-dependent neoplasm. Conflicting results regarding the clinical correlation between breast cancer and thyroid diseases have been reported. The aim of this study was to determine the goiter prevalence, ...

Protocol Code: BRAJAC British Columbia Cancer Agency Revised 01 Sept 1998 h:\everyone\systemic\pharmacy\patinfo\brajac.doc 1 Patient Information Sheet for Breast Cancer Chemotherapy Program AC A : Doxorubicin (also known as Adriamycin) C : Cyclophosphamide Indications: You have been recommended to take this drug treatment (Chemotherapy) in the hope of killing cancer cells that could have spread to other parts of your body before your surgery (adjuvant chemotherapy). This treatment may reduce the chance of your breast cancer coming back. Your overall survival or chance of cure may be improved. General Treatment Plan: The 2 drugs, Doxorubicin and Cyclophosphamide, will be injected into a vein in your arm once every 3 weeks for a total of 4 treatments. A blood test is required before each treatment. If other doctors or dentists are seeing ...

Protocol Code: BRAJCMFpo British Columbia Cancer Agency 18 Feb 1998 h:\everyone\systemic\pharmacy\patinfo\brajcmfo.doc 1 Patient Information Sheet for Adjuvant Breast Cancer Chemotherapy Program CMFpo (with cyclophosphamide given by mouth) C : Cyclophosphamide M: Methotrexate F : 5-Fluorouracil Indications: You have been recommended to take this drug treatment (Chemotherapy) in the hope of killing cancer cells that could have spread to other parts of your body before your surgery (adjuvant chemotherapy). This treatment may reduce the chance of your breast cancer coming back. Your overall survival or chance of cure may be improved. General Treatment Plan: This treatment program consists of both pills and injections given over 28 days. Each 28-day treatment starts on day 1 and is described as a “cycle”. The 2 drugs, ...

breast cancer National Breast Cancer Foundation 2004 Kathleen Cuningham Grants for Breast Cancer Research State Investigator Institution Project title Granted Total Lay Description NSW Dr Graham Mann Westmead Institute for Cancer Research Mapping and identification of novel breast cancer susceptibility genes $213,500 This project takes advantage of a large collaborative network of researchers (KconFab). It is a continuation of a search for genes other than BRCA1 and BRCA2 that cause breast cancer risk in families. Based on experience with previously discovered breast cancer genes, this research will shed light on the types of changes that drive the malignancy of breast cancer cells. It will have implications for improved prevention, diagnosis and treatment ...

Inflammatory breast cancer This factsheet discusses the main aspects of inflammatory breast cancer . We recommend that you read it with our booklets about diagnosing and treating breast cancer . We hope that it helps you to discuss any questions you may have with your cancer specialist or breast care nurse and to be involved in your treatment plan. What is inflammatory breast cancer ? Inflammatory breast cancer is so called because the overlying skin of the breast has a reddened appearance – similar to that seen with some infections of the breast . In patients with inflammatory breast cancer , the reddened appearance is caused by breast cancer cells blocking tiny channels in the breast tissue called lymph channels. The lymph channels are part of the lymphatic system involved in the body’s defence against infections. ...

Aspirin and Breast Cancer The role of inflammation in breast cancer is a subject of intense study. Specifically the role of the inflammatory enzymes COX-1 and Cox-2 and drugs that act as COX-2 inhibitors in several cancers, including breast cancer , is currently an area of research interest. Anti-inflammatory drugs, including aspirin, have shown promise in the treatment of cardiovascular diseases and are being studied in the reduction of other cancers such as colon and breast cancer . Aspirin has become the focus of the latest research report, published in the May 25, 2004 Journal of the American Medical Association. Aspirin and ibuprofen are part of a group of anti- inflammatory drugs called non-steroidal anti-inflammatory drugs (NSAIDs). In the inflammatory process the COX enzymes are abundant. COX-2 has been found to be associated with some cancers, including breast cancer ...

E-mail Rumor Inaccurately Links Antiperspirants and Breast Cancer An urban legend that has been broadly circulated recently states that the use of antiperspirants is the leading cause of breast cancer . This is an inaccurate statement that is causing alarm for many women. Apparently, some people think that perspiration is a way for the body to rid itself of "toxins." In reality, perspiration is a mechanism to regulate body temperature. The fluid we call "sweat" does not contain any toxins. It contains natural bodily wastes like water, urea, salt and fatty substances. Preventing perspiration under the arms does not affect the body's ability to eliminate these wastes, as they can be eliminated through other areas of the body such as the soles of the feet and hands and most other body surfaces. Extensive research has been done on the risk factors associated with developing breast cancer , ...

B310 Characterisation of Breast Cancer Cells for Neuropeptide Y Binding Sites C.M. Deckert a , A. Böttner b , N. Koglin a and A.G. Beck-Sickinger a a Institute of Biochemistry, University of Leipzig, Germany b Hospital for Children and Adolescents, University of Leipzig, Germany The neuropeptide NPY is one of the most abundant neuropeptides in the mammalian nervous system. It has a lot of different functions in the central nervous system such as stimulating the feeding behaviour and inhibition of anxiety. Additionally it also plays an important role in the peripheral nervous system by mediating gastrointestinal motility and secretion, insulin release and renal secretion. The effect of NPY is mediated by six receptor subtypes that all belong to the family of G- protein coupled receptors. ...

Susan G. Komen Breast Cancer Foundation Mid-Kansas Affiliate Member / Volunteer Profile Name: Address:_ City: _ Zip: _ Day Phone: _ Evening Phone:__ Fax: E-Mail:_ Occupation:_ Are you a breast cancer survivor?__ If Yes, do you wish to be invited to survivor events? __ Please check the local activities in which you are interested in helping: Membership/volunteer Committee Data Processing Speaker’s Bureau Education Committee Special Events planning/staffing Telephone Committee Fundraising/development Committee Survivor events Witnessing in the Heartland Communications/Newsletter Mammography program Lee Denim day RACE FOR THE CURE® Team Committee Race Day set-up Food Committee Survivor Table Brochure Deliveries In-Memory Table Sponsors / door prizes Water Stations Registration/packet pick-up ...

Novartis International AG Novartis Communications CH-4002 Basel Switzerland Tel + 41 61 324 2200 Fax + 41 61 324 3300 Internet Address: http://www.novartis.com 1/3 MEDIA RELEASE • COMMUNIQUE AUX MEDIA • MEDIENMITTEILUNG Compelling disease-free survival results in breast cancer trial prompt independent researchers to offer patients the opportunity to switch to Femara ‚ , as reported in New England Journal of Medicine Interim results from first study to explore post-tamoxifen use of Femara ‚ (letrozole) in postmenopausal women with early breast cancer showed dramatically reduced risk of recurrence (43%) and significantly improved disease-free survival Basel, Switzerland, 9 October 2003—Postmenopausal women with early breast cancer who completed five years of post-surgical hormonal ...

breast cancer Biology 207 Spring 2004 Biology of Cancer Lecture 23 " Breast Cancer " Readings: King p. 278, Bazell (1998) Her-2 Outline: 1. Breast cancer statistics 2. Major types of breast cancer 3. Risk factors 4. Detection of breast cancer 5. Treatments Lecture: 1. Breast cancer statistics --1:8 chance of breast cancer for women in their lifetimes --Leading cause of cancer death in women aged 40-55 --Male breast cancer about 1% of cases 2. Major types of breast cancer Breast --specialized gland that produces milk to nourish infants. Glands--epithelia that secrete substances. Anatomy--lobules=site of milk production &nbs...

Overview: The Florida Breast Cancer Coalition Research Foundation (FBCCRF) is dedicated to the eradication of breast cancer through research, advocacy, and education. As an affiliate of the National Breast Cancer Coalition, we have been successful in securing federal funding for breast cancer research, improved access for high quality breast cancer screenings, diagnosis, and treatment; and increased influence and participation of breast cancer survivors in research and policy decisions. One of our key objectives is to ensure equal access to quality health care without fear of discrimination. In response to recent inquiries about pending healthcare legislation, FBCCRF has developed this position paper on quality health care in the state of Florida. Background: There is currently a healthcare crisis in the US, as well as in Florida, which needs to be addressed. ...

Cardinal Brands, Inc. Launches Campaign to Encourage Breast Cancer Awareness Page 1 of 2 Cardinal Brands, Inc. Launches Campaign to Encourage Breast Cancer Awareness —new website and portion of proceeds from new telephone message book sales to go to breast cancer education and research— St. Louis (June 6, 2002) – Cardinal Brands Inc., an industry leader in the design, development and manufacturing of office products, today announced the launch of its breast cancer awareness campaign that includes a new website with educational links, and a donation program to several national breast cancer foundations. The campaign was implemented to drive awareness of this debilitating disease, and to encourage other organizations to offer much needed support. Cardinal Brands will be donating a portion of its proceeds from sales of its Adams™ brand Write ‘n Stick™ telephone ...

BREAST CANCER FACT SHEET Breast Cancer Statistics • One in nine women is expected to develop breast cancer during her lifetime; one in 27 will die of it. 1 • Breast cancer is the most frequently diagnosed cancer in Canadian women. 2 • Breast cancer continues to lead in incidence among Canadian women, with more than twice as many new cases as lung cancer . 1 • Since 1988, breast cancer incidence rates have risen by 10% but death rates have dropped by 19%. 2 • Breast , lung and colorectal cancers account for at least 50% of the new cancer cases in women. 1 • Incidence by age group: 3 · 22% of breast cancer cases occur in women under age 50 · 48% of cases occur in women ages 50 to 69 · 30% of cases ...

5005 LBJ Freeway Suite 250 Dallas, Texas 75244 Tel: 972.855.1600 Fax: 972.855.1605 Helpline: 1.800 I’M AWARE® www.komen.org Breast Cancer Facts An estimated 215,990 new invasive cases of breast cancer are expected to occur among women in the United States during 2004. An estimated 1,450 new cases of breast cancer will be diagnosed in men in 2004. An estimated 40,110 women will die from breast cancer in 2004. An estimated 470 men will die from breast cancer in 2004. The five-year relative survival rate for women with localized breast cancer is more than 95 percent. Breast cancer is the leading cancer site among American women and is second only to lung cancer in cancer deaths. One woman is diagnosed with breast cancer every 3 minutes, and one woman will die of breast cancer every ...

Breast cancer Fshould ophthalmologists now be involved in screening? CM Wood Eye (2004) 18, 1–2. doi:10.1038/sj.eye.6700534 What is the commonest intraocular tumour? The majority of ophthalmologists if answering from their own clinical experience would pick uveal malignant melanoma. Indeed, two publications from the Wills Eye Hospital reporting referral of only 420 metastatic tumours compared to 3000 malignant melanomas over similar 20 year periods would appear to confirm this. 1,2 However, pathological and autopsy studies in the literature from the 1960s onwards indicated that up to 10% of patients dying of malignant disease may have uveal metastases, 3,4 with an estimated 66 000 patients having ocular metastases in the USA alone in 1993. 5 So why is there such an apparent disparity between the ...

H:\MHRA\Epinet\MillionWomenStudy\Aug2003FINAL HORMONE REPLACEMENT THERAPY (HRT) AND BREAST CANCER – IMPORTANT NEW INFORMATION You may have seen in the news that a large study in the UK, the Million Women Study, has just published its results on the risk of breast cancer with various types of HRT. This study shows that the level of risk associated with use of combined (oestrogen plus progestogen) HRT products is substantially higher than previously thought. If, after reading the information below, you are concerned, make a routine appointment to see your doctor. Use of HRT In the UK, HRT products are licensed for helping relieve the unpleasant symptoms of the menopause, including hot flushes, vaginal dryness and night sweats. Some HRT products are also licensed for the longer-term prevention of osteoporosis, which can cause bone fractures. Million Women Study findings This ...

MHRA\Epinet\MillionWomenStudy\Aug2003FINAL Hormone replacement therapy (HRT) and breast cancer – results of the UK Million Women Study Dear Health Professional This message provides information to help you advise women who are using HRT and who may be concerned about their risk of breast cancer following today’s publication in the Lancet of the UK Million Women Study. The Committee on Safety of Medicines (CSM) and its expert working group (EWG) on HRT have reviewed this study. The key points are: · The previously described small increase in risk of breast cancer in association with oestrogen-only products has been confirmed. · The increased risk of breast cancer in association with use of combined (oestrogen plus progestogen – both continuous and sequential regimens) HRT is substantially higher than with oestrogen-only therapy (see table below). ...

BREAST CANCER SUPPORT & RESOURCE SERVICES 785 Queen Street East, Toronto, ON M4M 1H5 1-888-778-3100 Some resources for partners of women with breast cancer Breast Cancer : Strategies for Husbands to Support Their Wives. Jim Eckmann. Nehemiah Publishing House: San Diego, CA., 1995. The purpose of this book, written by a trial attorney who lives in California, is to “give you background, strategies and guidelines to assist your wife.” In his view, a husband committed to his wife’s recovery is at least as important as all the chemicals, radiation, and surgery that she will receive. Includes a chapter of scriptural references of comfort for patients. Helping Your Mate Face Breast Cancer : Tips for becoming an effective support partner for the one you love during the breast cancer experience. Judy Kneece, RN. EduCare Publishing: ...

THE STATEMENT OF BARCELONA THE FUTURE OF BREAST CANCER RESEARCH IN DANGER Michael Baum, Mary Buchanan, Jose Baselga, Luigi Cataliotti Jacek Jassem and Martine Piccart INTRODUCTION This statement has been prepared by the scientific committee of the 3 rd European breast cancer conference that was held in Barcelona from the 19 th the 23 rd March 2002. This follows an open debate by the participants of the conference at a plenary session on Saturday the 23 rd March. The agenda for this discussion had been set by the scientific committee following private discussions where we recognised that there was a pan-European concern about the future of clinical and translational research for cancer in general and breast cancer in particular. BREAST CANCER IN EUROPE Breast cancer is the commonest malignancy ...